The Invisible Burden: How Systemic Inequity Stalls Sarcoidosis Research and What Philanthropy Can Do

Sarcoidosis, a complex and often debilitating inflammatory disease, remains a medical enigma that continues to evade a comprehensive cure. While it affects roughly 150,000 to 200,000 individuals in the United States, its impact is far from equitable. The disease, characterized by the growth of tiny collections of inflammatory cells called granulomas, disproportionately ravages the bodies of Black Americans, particularly Black women.

As the Milken Institute and the Ann Theodore Foundation recently discovered while attempting to launch a clinical trial for a new therapeutic, the challenge of treating sarcoidosis is twofold: the biological complexity of the disease itself and the deep-seated systemic inequities that dictate who receives care, who participates in research, and ultimately, who survives.

The Anatomy of an Understudied Disease

Sarcoidosis is a systemic inflammatory condition of unknown origin. It is a chameleon of the medical world, manifesting differently in every patient. For some, it is a transient, self-limiting condition that fades with time. For others, it is a chronic, recurring nightmare marked by debilitating fatigue, joint pain, and "brain fog." Depending on the organs targeted—which can include the lungs, eyes, skin, or heart—the disease may cause chest tightness, blurred vision, disfiguring skin scarring, or life-threatening heart rhythm disturbances.

Despite its potential for irreversible organ damage or death, sarcoidosis has historically languished in the shadows of underfunded research. Because the symptoms are often generalized and non-specific, patients frequently endure a grueling "diagnostic odyssey" lasting several years. By the time many receive a formal diagnosis, their disease has often progressed to a stage where only damage-mitigation is possible. Current standard-of-care treatments, such as corticosteroids and harsh chemotherapeutics, are blunt instruments that offer little relief from the disease’s root cause and often carry their own severe side effects.

A Disproportionate Impact: By the Numbers

The scientific gap in sarcoidosis research is not just a failure of medicine; it is a failure of social justice. The statistics regarding who bears the burden of this disease are staggering:

• Prevalence: Black Americans are 2.2 to 5.6 times more likely to be diagnosed with sarcoidosis than their White, Hispanic, or Asian counterparts.
• The Gender Gap: Black women carry the highest prevalence of any demographic group. Their rate of diagnosis is double that of Black men and three to six times higher than that of White, Asian, and Hispanic women.
• Clinical Exclusion: Despite this profound disparity, Black patients represent as little as 5 percent of clinical trial participants in interstitial lung disease studies.

When research samples fail to reflect the population most impacted by a disease, the science itself becomes incomplete. When clinical trials are designed without the participation of the communities they are meant to serve, the resulting therapies may be less effective—or even unsafe—for those groups.

Chronology of a Crisis: From Historical Mistrust to Modern Barriers

The current state of sarcoidosis care is the result of decades of systemic failures. The roots of these disparities are firmly planted in a history of medical discrimination and the exclusion of Black individuals from the biomedical establishment.

1. The Erosion of Trust

The reluctance of many Black Americans to participate in clinical trials is not a matter of choice; it is a rational response to historical malpractice and systemic racism within the medical system. When marginalized communities have been treated as subjects rather than partners, or have been consistently dismissed by clinicians, trust is fractured.

2. Structural Logistical Barriers

Even when Black patients are offered the opportunity to participate in trials, the "invisible costs" are often prohibitive. A survey by the Foundation for Sarcoidosis Research found that barriers such as the necessity of taking time off work, the cost of childcare, and the burden of transportation are primary deterrents to participation. These are not individual failures; they are the consequences of a socioeconomic structure that penalizes those who are already struggling with chronic illness.

3. The Professional Pipeline Deficit

The exclusion of Black Americans from the biomedical ecosystem extends to the laboratory and the exam room. As of 2018, only 5 percent of practicing physicians in the U.S. were Black—a figure that has remained stagnant. Without representation in the ranks of researchers, principal investigators, and medical leadership, the questions asked in the lab are rarely the questions that matter most to Black communities.

The Role of Philanthropy: Moving Where Government Cannot

In the current landscape, federal research funding—primarily through the National Institutes of Health (NIH)—is often sluggish, bound by bureaucratic red tape and shifting political winds. This is where strategic, nimble philanthropy serves as a critical catalyst.

The partnership between the Milken Institute and the Ann Theodore Foundation offers a blueprint for the future. By directing over $500,000 toward a clinical study of a promising therapeutic—a drug already FDA-approved for other inflammatory conditions but lacking data for sarcoidosis—they are demonstrating how private capital can "fast-track" research. This is not about replacing government funding, but about proving the viability of new treatments so that larger, slower institutional engines can take over.

Strengthening the Pipeline: The HBCU Leverage Point

Perhaps the most potent strategy for closing the research gap lies in the intentional investment in Historically Black Colleges and Universities (HBCUs). These institutions have proven themselves to be the most efficient engines for diversifying the American healthcare workforce.

The HBCU Impact

• Workforce Representation: While HBCUs make up only 2.3 percent of U.S. medical schools, they have historically produced nearly 70 percent of Black physicians and dentists in the United States.
• Community Proximity: HBCU graduates are statistically more likely to return to medically underserved communities, closing the gap in primary care where diseases like sarcoidosis are first identified.
• The Resource Gap: Despite their outsized impact, HBCUs are chronically underfunded. For context, in 2023, the entirety of research funding for all HBCUs combined was less than one-fifth of the funding awarded to a single institution, Johns Hopkins University.

To ignore the potential of HBCUs is to ignore the most effective tool available for dismantling systemic health inequities. By investing in the research infrastructure of HBCUs—such as supporting the newly formed Association of HBCU Research Institutions—philanthropists can ensure that the next generation of medical breakthroughs is built upon a foundation of equity and community-led science.

Implications for the Future

The lessons learned from the struggle for sarcoidosis research have implications that stretch far beyond one disease. We are witnessing a fundamental shift in how the medical establishment must view its mission. The "one-size-fits-all" model of medicine has consistently failed to provide equitable health outcomes for Black Americans, whether in the context of asthma, cancer, hypertension, or inflammatory diseases like sarcoidosis.

True medical progress requires a three-pronged approach:

1. Direct Philanthropic Intervention: Moving away from traditional, slow-moving grant cycles toward flexible, fast-moving investments that can pivot to meet the needs of the patient population.
2. Structural Investment in HBCUs: Treating these institutions as top-tier research partners, rather than afterthoughts, to build a sustainable pipeline of Black researchers and clinicians.
3. Institutional Reckoning: Acknowledging the historical erosion of trust and actively working to rebuild it through transparent, community-engaged research practices that address the logistical and economic realities of patients.

The science of medicine is only as strong as its reach. If we continue to exclude the populations most affected by chronic, life-altering conditions, we are not just failing those communities—we are failing the potential of medical science itself. By prioritizing equity and leveraging institutions that have long done more with less, we can move toward a future where a diagnosis of sarcoidosis is no longer a life sentence of uncertainty, but a manageable condition supported by science that is as diverse and inclusive as the people it serves.